PURPOSE: Amplification of the MYCN gene strongly correlates with advanced stage, rapid tumor progression and poor prognosis in neuroblastoma (NB). Several genes in the MYCN amplicon, including the DEAD box polypeptide 1 (DDX1) gene, and neuroblastoma-amplified gene (NAG gene), have been found to be frequently co-amplified with MYCN in NB. The aim of this study was to clarify the prognostic significance of the co-amplification or overexpression of DDX1 and NAG with MYCN. PROCEDURE: The gene copy numbers and mRNA expression levels of MYCN, DDX1, and NAG in 113 primary NBs were determined by the real-time quantitative polymerase chain reaction or quantitative reverse transcriptase/polymerase chain reaction assay. The relationships between gene co-amplification/overexpression status and stage, age at diagnosis, and overall survival were analyzed. RESULTS: For evaluating the frequency of DDX1 and NAG co-amplification, it proved appropriate to discriminate NBs with <40 copies of MYCN amplification from those with > or =40 copies of MYCN (DDX1, p = 0.00058; NAG, p = 0.0242, chi(2) for independence test). In patients with MYCN-amplified NB aged > or =18 months, those with tumor with enhanced DDX1 expression and low-NAG expression showed a significantly better outcome than those with low-DDX1 expression or enhanced NAG expression (p = 0.0245, log-rank test). None of the gene expression statuses had a significant relation to disease stage or survival for patients <18 months old. No relationship between any gene co-amplification status and disease stage, age at diagnosis, or overall survival was found. CONCLUSIONS: Our findings suggest that there may be a subset of NB in which enhanced DDX1 and low-NAG expression consequent to DDX1 co-amplification without NAG amplification contributes to susceptibility to intensive therapy. A larger study using an age cut-off of 18 months will be required.
PURPOSE: Amplification of the MYCN gene strongly correlates with advanced stage, rapid tumor progression and poor prognosis in neuroblastoma (NB). Several genes in the MYCN amplicon, including the DEAD box polypeptide 1 (DDX1) gene, and neuroblastoma-amplified gene (NAG gene), have been found to be frequently co-amplified with MYCN in NB. The aim of this study was to clarify the prognostic significance of the co-amplification or overexpression of DDX1 and NAG with MYCN. PROCEDURE: The gene copy numbers and mRNA expression levels of MYCN, DDX1, and NAG in 113 primary NBs were determined by the real-time quantitative polymerase chain reaction or quantitative reverse transcriptase/polymerase chain reaction assay. The relationships between gene co-amplification/overexpression status and stage, age at diagnosis, and overall survival were analyzed. RESULTS: For evaluating the frequency of DDX1 and NAG co-amplification, it proved appropriate to discriminate NBs with <40 copies of MYCN amplification from those with > or =40 copies of MYCN (DDX1, p = 0.00058; NAG, p = 0.0242, chi(2) for independence test). In patients with MYCN-amplified NB aged > or =18 months, those with tumor with enhanced DDX1 expression and low-NAG expression showed a significantly better outcome than those with low-DDX1 expression or enhanced NAG expression (p = 0.0245, log-rank test). None of the gene expression statuses had a significant relation to disease stage or survival for patients <18 months old. No relationship between any gene co-amplification status and disease stage, age at diagnosis, or overall survival was found. CONCLUSIONS: Our findings suggest that there may be a subset of NB in which enhanced DDX1 and low-NAG expression consequent to DDX1 co-amplification without NAG amplification contributes to susceptibility to intensive therapy. A larger study using an age cut-off of 18 months will be required.
Authors: Katleen De Preter; Frank Speleman; Valérie Combaret; John Lunec; Julian Board; Andy Pearson; Anne De Paepe; Nadine Van Roy; Geneviève Laureys; Jo Vandesompele Journal: J Clin Oncol Date: 2005-05-01 Impact factor: 44.544
Authors: H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay Journal: Cancer Date: 2001-11-01 Impact factor: 6.860
Authors: Wendy B London; Luca Boni; Thorsten Simon; Frank Berthold; Clare Twist; Mary Lou Schmidt; Robert P Castleberry; Katherine K Matthay; Susan L Cohn; Bruno De Bernardi Journal: Cancer Lett Date: 2005-10-18 Impact factor: 8.679
Authors: Thomas Santarius; Janet Shipley; Daniel Brewer; Michael R Stratton; Colin S Cooper Journal: Nat Rev Cancer Date: 2010-01 Impact factor: 60.716
Authors: Cornelia Stock; Eva Bozsaky; Franz Watzinger; Ulrike Poetschger; Lukas Orel; Thomas Lion; Agata Kowalska; Peter F Ambros Journal: Am J Pathol Date: 2007-12-28 Impact factor: 4.307
Authors: H E Wheeler; E R Gamazon; A L Stark; P H O'Donnell; L K Gorsic; R S Huang; N J Cox; M E Dolan Journal: Pharmacogenomics J Date: 2011-08-16 Impact factor: 3.550
Authors: Eva Villamón; Ana P Berbegall; Marta Piqueras; Irene Tadeo; Victoria Castel; Anna Djos; Tommy Martinsson; Samuel Navarro; Rosa Noguera Journal: PLoS One Date: 2013-01-14 Impact factor: 3.240